Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 + Gastric Cancer”

366 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 366 results

Large-scale testing (Phase 3)Looking for participantsNCT06901531
What this trial is testing

Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc. 500
Early research (Phase 1)Study completedNCT01613950
What this trial is testing

PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer

Who this might be right for
Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
Novartis Pharmaceuticals 18
Not applicableLooking for participantsNCT07607119
What this trial is testing

PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer

Who this might be right for
Gastric AdenocarcinomaStomach NeoplasmsLocally Advanced Gastric Cancer+1 more
Samsung Medical Center 53
Post-approval studies (Phase 4)Not Yet RecruitingNCT07829757
What this trial is testing

Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Early research (Phase 1)Ended earlyNCT02512237
What this trial is testing

A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression

Who this might be right for
Breast NeoplasmsStomach Neoplasms
Zhejiang Medicine Co., Ltd. 9
Testing effectiveness (Phase 2)Study completedNCT03929666
What this trial is testing

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Who this might be right for
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals 74
Testing effectiveness (Phase 2)UnknownNCT05141747
What this trial is testing

MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.

Who this might be right for
Locally Advanced Gastric CancerMetastatic HER2 Positive Gastroesophageal Junction Cancer
Shanghai Miracogen Inc. 60
Testing effectiveness (Phase 2)Ended earlyNCT00447226
What this trial is testing

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

Who this might be right for
Cancer
GlaxoSmithKline 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07126561
What this trial is testing

Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers

Who this might be right for
HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2
University of Chicago 43
Early research (Phase 1)Active Not RecruitingNCT05382364
What this trial is testing

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

Who this might be right for
Metastatic HER2+ Advanced Breast CancerBreast NeoplasmsGastric or Gastroesophageal Junction Adenocarcinoma (GEC)+1 more
Pfizer 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT06136897
What this trial is testing

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

Who this might be right for
Malignant Solid Neoplasm
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Looking for participantsNCT06750185
What this trial is testing

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
BioNTech SE 248
Large-scale testing (Phase 3)Looking for participantsNCT05677490
What this trial is testing

MFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Who this might be right for
Advanced Esophageal AdenocarcinomaAdvanced Gastric AdenocarcinomaAdvanced Gastroesophageal Junction Adenocarcinoma+12 more
Alliance for Clinical Trials in Oncology 382
Very early researchUnknownNCT05411432
What this trial is testing

Clinical Study of 68Ga Labeled HER2 Affibody Analogues

Who this might be right for
HER2-positive Breast Cancer and Gastric Cancer
Xijing Hospital 56
Testing effectiveness (Phase 2)Study completedNCT02015169
What this trial is testing

Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis

Who this might be right for
HER2-positive Gastric Cancer Patients With Liver Metastasis
Samsung Medical Center 32
Large-scale testing (Phase 3)Active Not RecruitingNCT03504397
What this trial is testing

Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06365008
What this trial is testing

Sintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric Cancer

Who this might be right for
Unresectable/Metastatic Gastric Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 27
Large-scale testing (Phase 3)Study completedNCT04499924
What this trial is testing

Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaEsophageal Adenocarcinoma
Seagen Inc. 17
Early research (Phase 1)Ended earlyNCT03680560
What this trial is testing

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

Who this might be right for
Solid TumorHER-2 Protein Overexpression
Cogent Biosciences, Inc. 6
Testing effectiveness (Phase 2)UnknownNCT05111444
What this trial is testing

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric NeoplasmsGastroesophageal Junction Adenocarcinoma
Fudan University 65
Next Page
50
565